Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Related Content:

University of Chicago Medicine Comprehensive Cancer CenterOncLive TVImmunotherapy in MelanomaMelanoma & Skin CancerImmuno-Oncology
Dr Garrot on Lutetium Lu 177 Vipivotide Tetraxetan in Older Patients with MCRPC
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases